Imatinib mesylate treatment in a dog with gastrointestinal stromal tumors
with a c-kit mutation |
| |
| Authors: | Mitsuhiro IRIE Yoshinori TAKEUCHI Yuzo OHTAKE Hitomi SUZUKI Nao NAGATA Takuma MIYOSHI Yumiko KAGAWA Tetsushi YAMAGAMI |
| |
| Institution: | 1)Shikoku Veterinary Medical Center, 3308–5 Ikenobe, Miki-cho, Kita-gun, Kagawa 761–0701, Japan;2)Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1–1–1 Yayoi, Bunkyo-ku, Tokyo 113–8657, Japan;3)North Labo, 8–35 2-chome-kita, Hongo, Shiroishi-ku, Sapporo-shi, Hokkaido 003–0027, Japan |
| |
| Abstract: | A 13-year-old spayed mixed-breed dog was diagnosed with a gastrointestinal
stromal tumor (GIST) after histopathological examination of an abdominal mass. Five months
after surgical resection of the tumor, we detected the recurrence of GIST with multiple
disseminated abdominal lesions. A sequence analysis of cDNA obtained from a biopsy of the
recurrent tumors revealed a mutation within exon 9 of the c-kit gene
(1523A>T, Asn508Ile), which has been shown to cause ligand-independent
phosphorylation of the KIT protein in GISTs and canine mast cell tumors (MCTs). Upon
detection of the recurrent tumors, we initiated treatment with imatinib mesylate (10
mg/kg, q 24 hr). After 2 months, the dog achieved complete remission. Our findings
indicate that canine GIST, and possibly MCT, may be responsive to molecular-targeted
therapy. |
| |
| Keywords: | canine gastrointestinal stromal tumor imatinib mesylate |
|
|
